In-Hospital Outcomes and Predictors of Paravalvular Leak and Deep Implantation With the Evolut R 34-mm Device: A Comparison With Smaller Evolut R Sizes.

Purpose: To compare in-hospital outcome of Evolut-R 34 mm vs. smaller Evolut-R devices and to identify predictors of paravalvular leak (PVL) and deep implantation specific for Evolut-R 34 mm.

Methods: This single-center retrospective study included 359 consecutive patients undergoing transcatheter aortic valve replacement (TAVR) with Evolut-R 34 mm (N = 84,23.

Transfemoral transcatheter aortic valve replacement without contrast medium using the Medtronic CoreValve system: a single center experience.

Background: Transcatheter aortic valve replacement (TAVR) in patients with chronic kidney disease (CKD) is challenging due to the high risk of contrast-induced nephropathy (CIN) and acute kidney injury (AKI). AKI dramatically reduces the clinical benefit of TAVR and is one of the strongest predictors of 30-day mortality as well as long-term adverse outcomes after TAVR. The aim of this study was to evaluate a protocol specifically designed to reduce the incidence of contrast-induced nephropathy (CIN) in advanced CKD patients screened for and undergoing TAVR.

Bioprinted thrombosis-on-a-chip.

Pathologic thrombosis kills more people than cancer and trauma combined; it is associated with significant disability and morbidity, and represents a major healthcare burden. Despite advancements in medical therapies and imaging, there is often incomplete resolution of the thrombus. The residual thrombus can undergo fibrotic changes over time through infiltration of fibroblasts from the surrounding tissues and eventually transform into a permanent clot often associated with post-thrombotic syndrome.

Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip.

Engineering cardiac tissues and organ models remains a great challenge due to the hierarchical structure of the native myocardium. The need of integrating blood vessels brings additional complexity, limiting the available approaches that are suitable to produce integrated cardiovascular organoids. In this work we propose a novel hybrid strategy based on 3D bioprinting, to fabricate endothelialized myocardium.

From cardiac tissue engineering to heart-on-a-chip: beating challenges.

The heart is one of the most vital organs in the human body, which actively pumps the blood through the vascular network to supply nutrients to as well as to extract wastes from all other organs, maintaining the homeostasis of the biological system. Over the past few decades, tremendous efforts have been exerted in engineering functional cardiac tissues for heart regeneration via biomimetic approaches. More recently, progress has been made toward the transformation of knowledge obtained from cardiac tissue engineering to building physiologically relevant microfluidic human heart models (i.